NCT06764329 is a Phase 1, PHASE2 clinical trial of Mesenchymal Stem Cells in Androgenetic Alopecia, sponsored by National Institute of Blood and Marrow Transplant (NIBMT), Pakistan.

Who is sponsoring NCT06764329?

NCT06764329 is sponsored by National Institute of Blood and Marrow Transplant (NIBMT), Pakistan.

What drugs are being tested in NCT06764329?

Interventions in NCT06764329: Mesenchymal Stem Cells, 0.9 % saline.

What condition does NCT06764329 study?

NCT06764329 studies Androgenetic Alopecia, Androgenetic Alopecia (AGA).

Is NCT06764329 still recruiting?

NCT06764329 is currently enrolling by invitation. Last updated 8 January 2025.

Last reviewed 2025-01-08 · How we verify

NCT06764329

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.

ENROLLING BY INVITATION Phase 1, PHASE2 Last updated 8 January 2025

What this trial tests

Phase 1, PHASE2 trial testing Mesenchymal Stem Cells in Androgenetic Alopecia in 70 participants. Enrolling by invitation.

Timeline

25 December 2024

Primary endpoint
30 June 2025

30 August 2025

Quick facts

Lead sponsor	National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Phase	Phase 1, PHASE2
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	70
Start date	25 December 2024
Primary completion	30 June 2025
Estimated completion	30 August 2025
Sites	2 locations across Pakistan

Drugs / interventions tested

Mesenchymal Stem Cells — full drug profile →
0.9 % saline

Conditions studied

Androgenetic Alopecia — all drugs for Androgenetic Alopecia →
Androgenetic Alopecia (AGA) — all drugs for Androgenetic Alopecia (AGA) →

Sponsor

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Who can join

Adults 20 to 59, male only, with Androgenetic Alopecia or Androgenetic Alopecia (AGA). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat adrogenic alopecia or male-pattern baldness, when compared to normal saline (given to placebo group). It will also assess the differences in patient satisfaction. The main focus will be to: 1. Compare the average hair regenerative effect of mesenchymal stem cells versus Placebo, in treatment of androgenetic alopecia. 2. To determine and compare the investigators assessment and patient satisfaction in both groups. Patients in treatment group will receive single session of MSC therapy injected in the scalp and placebo group will receive 0.9% saline solution. The participants will be followed for 12 weeks. The hair density and thickness will be mesured along with clinicians assessment and participant's satisfaction level.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Mesenchymal Stem Cells

Trials testing the same drug.

NCT06888973 — Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases · Phase 1, PHASE2 · enrolling by invitation
NCT06205342 — Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain · EARLY_PHASE1 · recruiting
NCT04519671 — Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease · Phase 1, PHASE2 · terminated
NCT04506073 — Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Park · Phase 2 · completed
NCT04519697 — Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease · Phase 1, PHASE2 · terminated

Other recruiting trials for Androgenetic Alopecia

Currently open trials in the same condition.

NCT07429253 — Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients · Phase 1, PHASE2 · recruiting
NCT06841458 — Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers · NA · recruiting

Other National Institute of Blood and Marrow Transplant (NIBMT), Pakistan trials

Trials by the same sponsor.

NCT06888973 — Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases · Phase 1, PHASE2 · enrolling by invitation
NCT06490627 — Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia · Phase 2 · recruiting
NCT06288932 — Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopen · Phase 3 · completed
NCT07039318 — Mesenchymal Stem Cell Therapy in Diabetic Kidney Disease-A Double-blind, Placebo-controlled, Randomized Clinical Trial · Phase 2 · completed
NCT06490601 — Long Term Beta Thalassemia Treatment: Findings From The Extension Period · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06764329 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Last refreshed: 8 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06764329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing